Trials / Withdrawn
WithdrawnNCT04408898
SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer
A Phase 2 Pilot Study of ADP-A2M4 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Adaptimmune · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to investigate the efficacy and safety of ADP-A2M4 in combination with pembrolizumab in HLA-A\*02 eligible and MAGE-A4 positive subjects with recurrent or metastatic Head and Neck cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | ADP-A2M4 in combination with pembrolizumab. | Single infusion of autologous genetically modified ADP-A2M4 Dose: 1.0 x109 to 10x109 transduced cells by a single intravenous infusion Repeat doses of pembrolizumab every 3 weeks. Dose: 200mg |
Timeline
- Start date
- 2020-07-02
- Primary completion
- 2021-12-01
- Completion
- 2021-12-01
- First posted
- 2020-05-29
- Last updated
- 2021-11-16
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04408898. Inclusion in this directory is not an endorsement.